-
News | 2021.07.27
Official signing of the association agreement between the Institut Pasteur and Université de Paris
On July 22, 2021, the Institut Pasteur and Université de Paris signed an association agreement. The agreement was signed in the Salle des Actes at the Institut Pasteur, a place that is steeped in history. The two institutions have a shared scientific ambition to contribute to progress in human health.Signing of the association agreement in the Salle des Actes. Credit: Institut Pasteur/Thomas Lang...
-
Document de presse | 2021.07.12
Ivermectin alleviates Covid-19 symptoms in an animal model
Since the start of the COVID-19 pandemic, various therapeutic approaches have been explored to tackle the disease. Scientists from the Institut Pasteur have shown that ivermectin, a drug used commercially as an antiparasitic treatment, offers protection from COVID-19 symptoms in an animal model. The scientists observed that taking ivermectin was associated with reduced inflammation in the...
-
Page avancée | 2021.08.09
Committing to Open Science
The Institut Pasteur has been acting in favor of Open Science by adopting two founding texts in May 2021: a Charter for Open Access to publications and a Policy for the management and sharing of research data and software code.
-
News | 2021.08.13
Low number of COVID-19 cases in Lao PTR: a seroprevalence study to confirm this figure
In 2020 when many countries around the world struggled with a large burden of COVID-19 cases, the Lao PDR stood out as a country with low reported numbers of SARS-CoV-2 infections. Was it due to a low circulation of the virus or to an inadequate surveillance system? To answer this question, a seroprevalence study has been conducted by Institut Pasteur du Laos, in collaboration with Institut...
-
Article | 2021.08.18
Your subscription is now complete
Thank your for your interest.You are now signed up for the Institut Pasteur newsletter.You will receive it once a month.You can easily unsubscribe at any moment by using the unsubscribe link that appears in each email.If you do not receive this email, please check your spam, bulk email folder or promotions tab in gmail.Institut Pasteur
-
Article | 2021.08.18
Your subscription is almost complete
Thank you for signing up for the Institut Pasteur newsletter.You will soon receive an email asking you to confirm this subscription.If you don’t receive this email, we suggest you check in your spam folder.Institut Pasteur
-
Page avancée | 2021.08.23
The Institut Pasteur Newsletter
Every month, all the scientific and institutional news of the Institut Pasteur: news, press releases, reports...
-
Document de presse | 2021.08.19
Immune checkpoint inhibitors improve cellular immunity against SARS-CoV-2
Researchers and doctors from the AP-HP, the Institut Pasteur, the University of Paris and the Sorbonne University, have carried out work on the effect of immune checkpoint inhibitors (anti-PD1 and anti-CTLA4) on cellular immunity against SARS-CoV-2. This work, the results of which suggest that these treatments are not deleterious during infection with COVID-19 and, on the contrary, seem to...
-
Document de presse | 2021.08.26
COVID-19: Will telecommuting strategies stop the virus from circulating?
How can we best organise on-site workplace and school attendance periods and remote work to slow the circulation of Sars-CoV-2? Is it better to separate classes? Bring your whole team in at the same time? Set this up on daily or weekly schedules? The COVID-19 pandemic has forced most countries to impose contact limitations in workplaces, universities and schools. Scientists from the CNRS,...
-
Fiche maladie | 2015.10.06
Candidiasis
Fungi (yeast) of the Candida genus can cause superficial infections affecting the mucous membranes or skin, and invasive infections, either localized to one organ or generalized throughout the body. Of the 200 known species of Candida, around twenty are responsible for human infection. Candida yeasts are often responsible for severe, hospital-acquired infections.
